Giulia Berzero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1820278/publications.pdf

Version: 2024-02-01

56	1,365	23	34
papers	citations	h-index	g-index
58	58	58	1908
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The molecular landscape of glioma in patients with Neurofibromatosis 1. Nature Medicine, 2019, 25, 176-187.	30.7	145
2	Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	74
3	<i>IDH</i> -wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro-Oncology, 2021, 23, 955-966.	1.2	73
4	Neurological Syndromes Associated with Anti-GAD Antibodies. International Journal of Molecular Sciences, 2020, 21, 3701.	4.1	64
5	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. Journal of Neurology, 2019, 266, 195-206.	3.6	58
6	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	58
7	Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment. Journal of the Neurological Sciences, 2016, 363, 182-187.	0.6	55
8	<i>FGFR1</i> actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology, 2018, 90, e2086-e2094.	1.1	47
9	Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	43
10	Diffuse gliomas classified by $1p/19q$ co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. Acta Neuropathologica, 2018, 135, 743-755.	7.7	42
11	Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 789-792.	1.9	41
12	Diagnosis and therapy of acute disseminated encephalomyelitis and its variants. Expert Review of Neurotherapeutics, 2016, 16, 83-101.	2.8	40
13	Current therapeutic approaches to diffuse grade II and III gliomas. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775203.	3 . 5	35
14	The clinical use of IDH1 and IDH2 mutations in gliomas. Expert Review of Molecular Diagnostics, 2018, 18, 1041-1051.	3.1	34
15	Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. European Journal of Cancer, 2017, 83, 28-31.	2.8	33
16	Motor neuron disease of paraneoplastic origin: a rare but treatable condition. Journal of Neurology, 2018, 265, 1590-1599.	3.6	31
17	Adoptive Transfer of <scp>JC</scp> Virusâ€6pecific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy. Annals of Neurology, 2021, 89, 769-779.	5.3	30
18	Strokeâ€like events after brain radiotherapy: a large series with longâ€term followâ€up. European Journal of Neurology, 2019, 26, 639-650.	3.3	29

#	Article	IF	Citations
19	Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	29
20	Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. Journal of Neurology, 2020, 267, 2083-2089.	3.6	28
21	Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e326.	6.0	26
22	Initial clinical presentation of young children with N-methyl- d -aspartate receptor encephalitis. European Journal of Paediatric Neurology, 2018, 22, 404-411.	1.6	26
23	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. Neurology, 2013, 81, 1014-1017.	1.1	25
24	Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. Acta Oncológica, 2018, 57, 403-411.	1.8	22
25	CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies. European Journal of Neurology, 2018, 25, e16-e17.	3.3	20
26	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. Neurology, 2014, 82, 1102-1102.	1.1	19
27	Spinal hemorrhage in eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Journal of Neurology, 2014, 261, 438-440.	3.6	19
28	Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	18
29	Herpes simplex encephalitis in glioma patients: a challenging diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 374-377.	1.9	17
30	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 455-462.	2.9	17
31	Neurological paraneoplastic syndromes: an update. Current Opinion in Oncology, 2018, 30, 359-367.	2.4	16
32	Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600â€"Mutant Adult Glial and Glioneuronal Tumors. Neurology, 2021, 97, e673-e683.	1.1	16
33	Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies. British Journal of Cancer, 2018, 119, 105-113.	6.4	15
34	Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 786-788.	1.9	13
35	Brain Metastases from Lung Cancer: Is MET an Actionable Target?. Cancers, 2019, 11, 271.	3.7	12
36	Guillain-Barré Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature. Oncologist, 2020, 25, e194-e197.	3.7	10

#	Article	IF	CITATIONS
37	Meningeal Melanomatosis: A Challenge for Timely Diagnosis. BioMed Research International, 2015, 2015, 1-6.	1.9	9
38	Episodic Memory Impairments in Primary Brain Tumor Patients. Archives of Clinical Neuropsychology, 2018, 33, 949-955.	0.5	9
39	Psychiatric symptoms in anti glutamic acid decarboxylase associated limbic encephalitis in adults: a systematic review. Neuroscience and Biobehavioral Reviews, 2020, 119, 128-137.	6.1	8
40	Late post-transplant anti-aquaporin-4 Ab-positive optic neuritis in a patient with AML. Bone Marrow Transplantation, 2015, 50, 1125-1126.	2.4	7
41	Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults. Neuro-Oncology, 2020, 22, 993-1005.	1.2	7
42	Facing Contrast-Enhancing Gliomas: Perfusion MRI in Grade III and Grade IV Gliomas according to Tumor Area. BioMed Research International, 2014, 2014, 1-5.	1.9	6
43	Lower motor neuron syndrome in a patient with HER2-positive metastatic breast cancer: A case report and review of the literature. Clinical Neurology and Neurosurgery, 2018, 172, 141-142.	1.4	5
44	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. Current Opinion in Oncology, 2020, 32, 603-612.	2.4	5
45	Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients. Neurological Sciences, 2021, 42, 1879-1886.	1.9	5
46	Cranial nerve palsies in patients with hematological malignancies: a case series. International Journal of Neuroscience, 2020, 130, 777-780.	1.6	4
47	Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity. Acta Oncol \tilde{A}^3 gica, 2020, 59, 484-489.	1.8	4
48	CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient. Neuro-Oncology, 2019, 21, 139-141.	1.2	3
49	Quantitative brain imaging analysis of neurological syndromes associated with anti-GAD antibodies. Neurolmage: Clinical, 2021, 32, 102826.	2.7	3
50	Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype Journal of Clinical Oncology, 2018, 36, 2005-2005.	1.6	3
51	Neuropathic pain, dysautonomia, and nerve hyperexcitability: Expanding the spectrum of LGI1 autoimmunity. Clinical Neurophysiology, 2019, 130, 248-250.	1.5	2
52	Impact of multiple sclerosis risk loci in postinfectious neurological syndromes. Multiple Sclerosis and Related Disorders, 2020, 44, 102326.	2.0	2
53	Viral Infections of the Nervous System. , 2015, , 75-92.		1
54	Gut microbiome alterations in antiâ€NMDA receptor encephalitis: caveats for result interpretation. Annals of Clinical and Translational Neurology, 2020, 7, 153-154.	3.7	1

#	Article	lF	CITATIONS
55	Diagnosing acute encephalitis in patients with hematological disorders: caveats and pitfalls. Journal of NeuroVirology, 2020, 26, 257-263.	2.1	O
56	Targeting glioblastoma stem-cells: a recurrent challenge in neuro-oncology. Translational Cancer Research, 2017, 6, S1197-S1199.	1.0	0